Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2013

01.02.2013 | review

Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications

verfasst von: Sonja Burgstaller, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Chronic myelomonocytic leukaemia (CMML) is a clonal disorder of the haematopoietic stem cell characterised by the presence of an absolute monocytosis in peripheral blood. The disease carries myelodysplastic and myeloproliferative features. This dilemma was sought to be overcome by the World Health Organization (WHO) in 2001, when CMML was classified within a new category of myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN). The identification of molecular markers in patients with CMML has dramatically increased over the past couple of years. However, the impact on prognosis and therapeutic interventions needs to be defined. Testing of new agents in the setting of CMML proves to be difficult due to limited number of patients. This review has a focus on current diagnosis including new molecular data and treatment of CMML.
Literatur
1.
Zurück zum Zitat Vardiman JW, Pierre R, Bain B, Bennett JM, Imbert M, Brunning RD, et al. WHO histological classification of myelodysplastic/myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: tumours of the haematopoietic and lympoid tissues. Lyon: International Agency for Research on Cancer (IARC) Press; 2001. pp. 47–59. Vardiman JW, Pierre R, Bain B, Bennett JM, Imbert M, Brunning RD, et al. WHO histological classification of myelodysplastic/myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: tumours of the haematopoietic and lympoid tissues. Lyon: International Agency for Research on Cancer (IARC) Press; 2001. pp. 47–59.
2.
Zurück zum Zitat Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. Leuk Lymphoma. 2011;52:92–100.PubMedCrossRef Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. Leuk Lymphoma. 2011;52:92–100.PubMedCrossRef
3.
Zurück zum Zitat Subira D, Font P, Villalon L, Serrano C, Askari E, Gongora E, et al. Immonophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders? Transl Res. 2008;151:240–5.PubMedCrossRef Subira D, Font P, Villalon L, Serrano C, Askari E, Gongora E, et al. Immonophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders? Transl Res. 2008;151:240–5.PubMedCrossRef
4.
Zurück zum Zitat Gorczyca W. Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukaemia (AML-M5), acute myelomonocytic leukaemia (AML-M4), and chronic myelomonocytic leukaemia (CMML). Methods Cell Biol. 2004;75:665–7.PubMedCrossRef Gorczyca W. Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukaemia (AML-M5), acute myelomonocytic leukaemia (AML-M4), and chronic myelomonocytic leukaemia (CMML). Methods Cell Biol. 2004;75:665–7.PubMedCrossRef
5.
Zurück zum Zitat Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol. 2005;124:799–806.PubMedCrossRef Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol. 2005;124:799–806.PubMedCrossRef
6.
Zurück zum Zitat Vardiman JW, Imbert M, Pierre R, Brunning RD, Bain B, Flandrin G, et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 49–52. Vardiman JW, Imbert M, Pierre R, Brunning RD, Bain B, Flandrin G, et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 49–52.
7.
Zurück zum Zitat Orazi A, Chiu R, O’Malley DP, Czader M, Allen SL, An C, Vance GH. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistolog. Mod Pathol. 2006;19:1536–45.PubMedCrossRef Orazi A, Chiu R, O’Malley DP, Czader M, Allen SL, An C, Vance GH. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistolog. Mod Pathol. 2006;19:1536–45.PubMedCrossRef
8.
Zurück zum Zitat Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res. 1998;22:871–8.PubMedCrossRef Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res. 1998;22:871–8.PubMedCrossRef
9.
Zurück zum Zitat Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol. 1988;6:1417–24.PubMed Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol. 1988;6:1417–24.PubMed
10.
Zurück zum Zitat Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia. 1990;4:766–70.PubMed Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia. 1990;4:766–70.PubMed
11.
Zurück zum Zitat McClure RF, Dewald GW, Hoyer JK, Hanson CA. Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol. 1999;106:445–54.PubMedCrossRef McClure RF, Dewald GW, Hoyer JK, Hanson CA. Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol. 1999;106:445–54.PubMedCrossRef
12.
Zurück zum Zitat Burgstaller S, Reiter A, Cross NCP. BCR-ABL negative chronic myeloid leukemia. Curr Hem Malignancy Rep. 2007;2:75–82.CrossRef Burgstaller S, Reiter A, Cross NCP. BCR-ABL negative chronic myeloid leukemia. Curr Hem Malignancy Rep. 2007;2:75–82.CrossRef
13.
Zurück zum Zitat Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.PubMedCrossRef Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.PubMedCrossRef
14.
Zurück zum Zitat Kosmider O, Gelsi-Bayer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutationis a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94:1676–81.PubMedCrossRef Kosmider O, Gelsi-Bayer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutationis a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94:1676–81.PubMedCrossRef
15.
Zurück zum Zitat Kohlmann A, Grossmann V, Klein H, Schindela S, Weiss T, Kazak B, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28:3858–65.PubMedCrossRef Kohlmann A, Grossmann V, Klein H, Schindela S, Weiss T, Kazak B, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28:3858–65.PubMedCrossRef
16.
Zurück zum Zitat Dunbar AJ, Gondek LP, O’Keefe CL, Makishima H, Rataul MS, Szpurka H, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68:10349–57. Dunbar AJ, Gondek LP, O’Keefe CL, Makishima H, Rataul MS, Szpurka H, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68:10349–57.
17.
Zurück zum Zitat Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res. 2010;16:2246–56.PubMedCrossRef Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res. 2010;16:2246–56.PubMedCrossRef
18.
Zurück zum Zitat Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zahng L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–8.PubMedCrossRef Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zahng L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–8.PubMedCrossRef
19.
Zurück zum Zitat Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, Francia di Celle P. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62:798–801.PubMedCrossRef Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, Francia di Celle P. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62:798–801.PubMedCrossRef
20.
Zurück zum Zitat Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182–92.PubMedCrossRef Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182–92.PubMedCrossRef
21.
Zurück zum Zitat Gelsi-Boyer V, Trouplin V, Adelaide J, Aceto N, Remy V, Pinson S, et al. Genome profiling of chronic myelomonoytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008;8:299. Gelsi-Boyer V, Trouplin V, Adelaide J, Aceto N, Remy V, Pinson S, et al. Genome profiling of chronic myelomonoytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008;8:299.
22.
Zurück zum Zitat Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, Shih LY. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009;23:1426–31.PubMedCrossRef Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, Shih LY. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009;23:1426–31.PubMedCrossRef
23.
Zurück zum Zitat Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndrome and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788–800.PubMedCrossRef Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndrome and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788–800.PubMedCrossRef
24.
Zurück zum Zitat Germing U, Kündgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004;45:1311–8.PubMedCrossRef Germing U, Kündgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004;45:1311–8.PubMedCrossRef
25.
Zurück zum Zitat Molica S, Iannaccuro P, Albeti A. Chronic myelomonocytic leukemia: a test of a proposed staging system. Am J Haematol. 1990;35:129–30.CrossRef Molica S, Iannaccuro P, Albeti A. Chronic myelomonocytic leukemia: a test of a proposed staging system. Am J Haematol. 1990;35:129–30.CrossRef
26.
Zurück zum Zitat Worsley A, Oscier DG, Stevens J, Darlow S, Figes A, Mufti GJ, Hamblin TJ. Prognostic features of chronic myelomonocytic leukemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68:17–21.PubMedCrossRef Worsley A, Oscier DG, Stevens J, Darlow S, Figes A, Mufti GJ, Hamblin TJ. Prognostic features of chronic myelomonocytic leukemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68:17–21.PubMedCrossRef
27.
Zurück zum Zitat Aul C, Ganttermann N, Neyll A, Germing U, Gerigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52–9.PubMed Aul C, Ganttermann N, Neyll A, Germing U, Gerigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52–9.PubMed
28.
Zurück zum Zitat Gonzales-Medina I, Bueno J, Torrequebrada A, Lopez A, Vallespi T, Massague I. Two groups of chronic myelomonocytic leukemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res. 2002;26:821–4.CrossRef Gonzales-Medina I, Bueno J, Torrequebrada A, Lopez A, Vallespi T, Massague I. Two groups of chronic myelomonocytic leukemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res. 2002;26:821–4.CrossRef
29.
Zurück zum Zitat Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002; 99: 840–9.PubMedCrossRef Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002; 99: 840–9.PubMedCrossRef
30.
Zurück zum Zitat Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognositc Scoring System. Leuk Lymphoma. 2007;48:1150–60.PubMedCrossRef Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognositc Scoring System. Leuk Lymphoma. 2007;48:1150–60.PubMedCrossRef
31.
Zurück zum Zitat Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood. 1996;88:2480–7.PubMed Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood. 1996;88:2480–7.PubMed
32.
Zurück zum Zitat Beran M, Estey E, O’Brien S, Giles FJ, Koller CA, Kornblau S, et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk lymphoma. 1998;31:521–31.PubMed Beran M, Estey E, O’Brien S, Giles FJ, Koller CA, Kornblau S, et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk lymphoma. 1998;31:521–31.PubMed
33.
Zurück zum Zitat Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.
34.
Zurück zum Zitat Wong E, Seymour JF, Kenealy M, Westerman D, Herbert K, Dickinson M. Treatment of chronic myelomonocytic leukemia with azacitidine. Leuk Lymphoma. 2012. Epub ahead of print. Wong E, Seymour JF, Kenealy M, Westerman D, Herbert K, Dickinson M. Treatment of chronic myelomonocytic leukemia with azacitidine. Leuk Lymphoma. 2012. Epub ahead of print.
35.
Zurück zum Zitat Feldman E, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O’Brien SG, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008;22:1707–11.PubMedCrossRef Feldman E, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O’Brien SG, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008;22:1707–11.PubMedCrossRef
36.
Zurück zum Zitat Sliitonen T, Timonen T, Juvonen E, Terävä V, Kutila A, Honkanen T, et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica. 2007;92:1119–22.CrossRef Sliitonen T, Timonen T, Juvonen E, Terävä V, Kutila A, Honkanen T, et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica. 2007;92:1119–22.CrossRef
37.
Zurück zum Zitat Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transpl. 2010. doi:10.1016/j.bbmt.2010.09.018. Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transpl. 2010. doi:10.1016/j.bbmt.2010.09.018.
Metadaten
Titel
Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications
verfasst von
Sonja Burgstaller, MD
Publikationsdatum
01.02.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0064-6

Weitere Artikel der Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013 Zur Ausgabe